Treatment for Contact Dermatitis of Hand

Phase-Based Progress Estimates
Dr Glynis Ablon MD, FAAD, Manhattan Beach, CA
Contact Dermatitis of Hand+3 More
All Sexes
What conditions do you have?

Study Summary

This study is intended to be a cross over study. Subjects will treat one hand while the contralateral hand acts as a control. At the end of 6 weeks the subject will be instructed to cease treatment of the test hand and commence treatment of the control hand for 6 weeks. Efficacy will be evaluated at 6 weeks after the beginning of the treatment and 12 weeks (end of crossover).

Eligible Conditions

  • Contact Dermatitis of Hand

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 1 Secondary · Reporting Duration: at 6-weeks

At 6 weeks
Subjective assessment of treatment response (POEM)
at 6-weeks
Reduction in the signs and symptoms of contact/irritant dermatitis of the hand according to a Modified SCORAD system

Trial Safety

Safety Progress

1 of 3

Trial Design

0 Treatment Group

25 Total Participants · 0 Treatment Group

Primary Treatment: Treatment · No Placebo Group · N/A

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: at 6-weeks
Closest Location: Dr Glynis Ablon MD, FAAD · Manhattan Beach, CA
N/AFirst Recorded Clinical Trial
1 TrialsResearching Contact Dermatitis of Hand
0 CompletedClinical Trials

Eligibility Criteria

Age 18+ · All Participants · 6 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
Subjects agree to use a non-mediated soap substitute supplied for their use during the study period (Syndet).
You are between the ages of 21 and 75 years.
You have mild to moderate atopic dermatitis of the hand.
Subjects agree to treat only one hand at a time for 6 weeks, the other acting as a control.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.